Last updated: August 8, 2026

Nasonex 24HR Allergy is the U.S. over-the-counter version of mometasone furoate nasal spray, a corticosteroid indicated for temporary relief of nasal congestion, sneezing, runny nose, and itchy nose caused by hay fever or other respiratory allergies. Its commercial position is based on brand recognition, once-daily dosing, and broad retail distribution rather than active-molecule exclusivity.

The product operates in a mature, highly substitutable market dominated by Flonase, generic fluticasone, Nasacort, Rhinocort, and store-brand intranasal corticosteroids. The U.S. OTC launch created a consumer-growth opportunity for Organon, but it also placed Nasonex directly against lower-priced generics. Organon does not publicly disclose standalone Nasonex 24HR Allergy revenue, so the product’s financial trajectory must be assessed through portfolio disclosures, channel dynamics, market structure, and regulatory status.

What is Nasonex 24HR Allergy and who markets it?

Nasonex 24HR Allergy contains mometasone furoate monohydrate equivalent to 50 micrograms of mometasone furoate per spray. The product is an aqueous nasal suspension delivered through a metered spray device. The labeled adult and adolescent dose is two sprays in each nostril once daily, with a reduction to one spray in each nostril once symptoms are controlled. Children aged two to 11 years use one spray in each nostril once daily under the product labeling.[1]

The original prescription product, Nasonex, was developed by Merck & Co. and approved by the FDA in the 1990s. The OTC U.S. product is associated with Organon, the company formed through Merck’s 2021 spinoff of its women’s health, established brands, and biosimilars businesses.[2]

Product profile

Attribute	Nasonex 24HR Allergy
Active ingredient	Mometasone furoate monohydrate
Drug class	Intranasal corticosteroid
U.S. status	Over-the-counter
Primary indication	Temporary relief of nasal allergy symptoms
Administration	Once daily
Dosage form	Metered nasal spray
Prescription predecessor	Nasonex
Commercial owner in U.S.	Organon-associated consumer-health business
Main competitors	Flonase, generic fluticasone, Nasacort, Rhinocort, store brands

The product’s principal differentiation is not a novel mechanism. Intranasal corticosteroids are an established category with similar efficacy profiles when used correctly. Nasonex competes through brand equity, product placement, packaging, perceived tolerability, and consumer advertising.

When did Nasonex 24HR Allergy become an OTC product?

Nasonex 24HR Allergy entered the U.S. OTC market after FDA approval of a nonprescription version of mometasone furoate nasal spray. The conversion followed the regulatory path used by other major intranasal corticosteroids, including Flonase and Nasacort.

The OTC transition changed the commercial model in several ways:

Consumers could select Nasonex without a physician visit or prescription.
Retail pharmacy and mass-market distribution became more important.
The product shifted from prescription reimbursement toward cash-pay and consumer-packaged-goods economics.
Brand advertising and shelf position became more important than formulary access.
Generic prescription competition remained a material price constraint.

The OTC format expanded the addressable consumer base but reduced the protection provided by prescription branding and physician-directed prescribing. Nasonex now competes at the point of purchase with several products that have similar labels and lower prices.

What patents protect Nasonex 24HR Allergy?

Nasonex 24HR Allergy has little practical patent protection in the U.S. The relevant composition, formulation, and use patents associated with the original Nasonex product are historical assets rather than meaningful barriers to current OTC competition.

The key patent-protection facts are:

Protection category	Current commercial relevance
Mometasone furoate active ingredient	Historical protection has expired
Original prescription formulation	Historical protection has expired or is no longer a meaningful barrier to generic entry
Once-daily allergy treatment	No meaningful exclusivity against competing intranasal steroids
OTC product label	Regulatory labeling rights do not prevent competing generic products
Spray-device configuration	Device or packaging claims may exist, but they do not protect the active ingredient market broadly
Method-of-use claims	Historical claims do not prevent generic intranasal corticosteroid competition

The FDA Orange Book is the principal U.S. source for listed patents and regulatory exclusivity associated with approved drug products.[3] Nasonex’s commercial risk is consistent with a legacy product whose principal molecule and formulation protections have expired. The current product’s protection is therefore based on trademarks, packaging, distribution, consumer awareness, and execution at retail.

Is Nasonex 24HR Allergy listed in the Orange Book?

The original prescription Nasonex NDA is part of the historical FDA approval record. Orange Book relevance is limited because the product’s principal patent estate has expired and the current consumer product is sold without prescription.

An Orange Book listing does not itself establish a current market barrier. The relevant question is whether an unexpired, enforceable patent blocks an ANDA or other competing approval. For mometasone furoate nasal spray, generic competition demonstrates that the active formulation is not protected by an effective remaining exclusivity position.

When did Nasonex lose exclusivity?

Nasonex lost effective prescription exclusivity years before the OTC launch. Generic mometasone furoate nasal sprays became available in the U.S. before Nasonex 24HR Allergy was commercialized as a consumer product.

The loss of exclusivity produced three commercial effects:

Prescription Nasonex faced substitution by lower-cost generic mometasone.
The branded product had to compete outside reimbursement channels.
The OTC launch relied on consumer conversion rather than protected prescription demand.

The OTC product may carry a different label, package, and regulatory approval from generic prescription products, but those differences do not create durable molecule-level exclusivity. A generic manufacturer can compete with mometasone nasal spray through prescription channels, while other OTC intranasal corticosteroids compete directly for the same consumer need.

How strong is the Nasonex patent estate?

The patent estate is weak as a current market defense. It may retain historical value for freedom-to-operate analysis, but it does not provide a credible basis for delaying broad competition.

Strength assessment

Factor	Assessment
Active-ingredient protection	Expired
Core formulation protection	Expired or commercially ineffective
Device protection	Potentially narrow and non-blocking
Method-of-use protection	Limited practical value
OTC regulatory exclusivity	Not a durable competitive barrier
Trademark protection	Relevant to brand pricing and shelf recognition
Manufacturing barrier	Low to moderate; nasal suspension production requires quality controls but is established technology
Litigation leverage	Low compared with products with active composition or device patents

The principal remaining intangible asset is the Nasonex trademark. Trademark protection can prevent confusingly similar branding, but it does not stop competitors from selling mometasone, fluticasone, triamcinolone, or budesonide nasal sprays.

What is the competitive landscape for Nasonex 24HR Allergy?

Nasonex competes in the intranasal allergy category, where genericization has reduced product-level differentiation. Flonase and generic fluticasone are the strongest competitive reference points. Nasacort and Rhinocort provide additional branded and generic alternatives.

Direct and adjacent competitors

Product	Active ingredient	Market position
Nasonex 24HR Allergy	Mometasone furoate	Branded OTC entrant with once-daily positioning
Flonase Allergy Relief	Fluticasone propionate	Major established OTC brand
Flonase Sensimist	Fluticasone furoate	Premium sensory and formulation positioning
Nasacort Allergy 24HR	Triamcinolone acetonide	Established OTC intranasal steroid
Rhinocort Allergy	Budesonide	Established branded and generic competitor
Generic mometasone	Mometasone furoate	Lower-priced prescription substitute
Store brands	Multiple corticosteroids	Price-led competition

Flonase has an important first-mover advantage in the U.S. OTC intranasal steroid market. Its brand has benefited from years of consumer advertising, high pharmacy visibility, and broad product extensions. Nasonex must therefore compete for incremental share rather than develop the category from a protected position.

The category is also exposed to seasonal demand. Spring and fall allergy periods can produce volume spikes, while winter demand depends more on perennial allergic rhinitis and retailer promotions. Weather, pollen intensity, air pollution, and consumer health spending influence annual results.

What drives Nasonex 24HR Allergy revenue?

Nasonex revenue depends on five principal variables: retail distribution, price, consumer awareness, repeat use, and competitive promotion.

Retail and consumer dynamics

The product’s OTC economics are determined by:

Mass-market pharmacy and grocery distribution
E-commerce availability
End-cap and shelf placement
Promotional discounts
Brand advertising
Seasonal allergy intensity
Private-label substitution
Retailer purchasing terms

A branded OTC nasal spray can generate higher gross profit per unit than a generic prescription product, but it also carries substantial marketing and trade-spend requirements. Consumer conversion is expensive when competing brands have larger advertising budgets and stronger unaided awareness.

Pricing pressure

Nasonex is vulnerable to a price gap against store brands and generic prescription mometasone. The product can preserve a premium only if consumers perceive meaningful advantages in trust, comfort, dosing convenience, or availability.

The once-daily regimen is commercially useful but not unique. Flonase, Nasacort, and Rhinocort also support once-daily use. Nasonex therefore has limited ability to sustain premium pricing solely through dosing frequency.

What is the financial trajectory for Nasonex 24HR Allergy?

The product’s financial trajectory is likely characterized by an initial launch contribution followed by normalization in a mature category. Public filings do not identify Nasonex 24HR Allergy as a standalone revenue line, and Organon reports results primarily by geographic region and business segment rather than by individual consumer brand.[2]

Expected trajectory

Period	Financial pattern
Pre-OTC period	Prescription brand erosion from generic mometasone
OTC launch	Incremental revenue from consumer access and retail distribution
Early commercialization	Higher marketing, listing, and promotional spending
Mature OTC phase	Volume depends on share retention and seasonal demand
Long-term phase	Price pressure, private-label substitution, and category competition constrain growth

The OTC launch can increase total brand sales even when average selling prices decline. That outcome depends on whether incremental consumer volume exceeds the loss of prescription revenue and whether Organon can control advertising and trade costs.

Standalone profitability cannot be calculated from public company filings because sales, marketing expense, gross margin, inventory, and operating income for Nasonex are not separately reported. Nasonex is part of a broader established-brands portfolio that includes products with different growth rates and margin profiles.

Revenue exposure

Nasonex is not expected to be a material driver of Organon’s consolidated financial profile compared with its largest products, including Nexplanon, NuvaRing-related products, biosimilars, and other established brands. Its commercial value is more likely to be incremental and portfolio-based than transformational.

The product can still matter strategically because OTC brands provide:

Consumer cash-pay exposure
Reduced dependence on prescription reimbursement
Potentially higher gross margins than commoditized generic products
Seasonal revenue diversification
Brand monetization after prescription exclusivity ends

What FDA regulatory status applies to Nasonex 24HR Allergy?

Nasonex 24HR Allergy is an FDA-authorized OTC drug product for temporary relief of nasal allergy symptoms. The product’s labeling covers use for adults and children within the labeled age range. The active ingredient is a corticosteroid, and the label directs consumers to seek medical advice for persistent or worsening symptoms.

The regulatory risks are typical for an OTC nasal corticosteroid:

Incorrect self-diagnosis of allergic rhinitis
Overuse or prolonged use without medical guidance
Nasal irritation or bleeding
Pediatric-use concerns
Manufacturing consistency for a suspension spray
Labeling compliance and advertising substantiation

FDA regulatory status supports market access but does not create meaningful competitive exclusivity. Competing nasal corticosteroids have similar OTC regulatory profiles.

What manufacturing and intellectual-property barriers affect Nasonex?

Manufacturing is more difficult than producing a simple oral tablet because the product requires a consistent suspension, metered-dose delivery, container-closure integrity, microbiological control, and reproducible spray performance.

The main technical requirements include:

Uniform particle dispersion
Reliable dose delivery throughout labeled use
Stable suspension behavior
Consistent actuator performance
Appropriate preservative and microbiological controls
Packaging that maintains product quality

These requirements create a quality and scale barrier, but they are not a strong exclusionary barrier. Multiple generic manufacturers have experience producing nasal corticosteroid sprays. Manufacturing capability can delay a poorly prepared entrant, but it is unlikely to prevent competition from established generic or consumer-health companies.

Which companies are challenging Nasonex commercially?

The principal commercial challengers are Haleon through Flonase, Chattem and related Sanofi consumer-health operations through Nasacort, Perrigo through private-label and store-brand products, and generic manufacturers selling mometasone, fluticasone, triamcinolone, or budesonide nasal sprays.

The competitive threat differs by channel:

Channel	Primary threat
Prescription	Generic mometasone
Pharmacy OTC	Flonase, Nasacort, Rhinocort
Mass retail	Store brands and private-label sprays
E-commerce	Price comparison and multi-pack discounts
Physician recommendation	Established intranasal steroid alternatives

No major biosimilar risk applies. Nasonex is a small-molecule chemical drug, not a biologic. The relevant competitive pathway is generic drug approval and OTC competition, not biosimilar interchangeability.

What generic entry risks exist for Nasonex?

Generic entry risk is already realized rather than prospective. Generic mometasone nasal sprays are established competitors, and the branded OTC product cannot rely on an unexpired patent to prevent substitution.

Future risks include:

Retailers expanding private-label mometasone or other intranasal steroids.
Generic manufacturers improving direct-to-consumer availability.
Price compression during peak allergy seasons.
Consumers shifting from branded sprays to lower-cost alternatives.
Competitors using sensory benefits, such as reduced aftertaste or softer spray delivery.
Retailers reducing shelf space for lower-velocity branded products.

A successful generic or private-label launch would likely affect Nasonex through price, promotional intensity, and retailer bargaining power rather than through a single patent challenge.

What patent litigation or Paragraph IV litigation affects Nasonex?

No current high-impact Paragraph IV litigation is central to the commercial outlook for Nasonex 24HR Allergy. Paragraph IV challenges were relevant during the transition from prescription Nasonex to generic mometasone nasal spray, but the market has moved beyond the principal exclusivity dispute.

Current litigation risk is more likely to involve:

Trademark infringement
Advertising claims
Product quality
OTC labeling
Consumer class actions
Retail and distribution agreements
Device or packaging disputes

These issues could create cost or reputational exposure, but they are unlikely to restore molecule-level exclusivity.

How does Nasonex compare with Flonase, Nasacort, and Rhinocort?

Dimension	Nasonex	Flonase	Nasacort	Rhinocort
Active ingredient	Mometasone	Fluticasone	Triamcinolone	Budesonide
OTC maturity	Newer OTC positioning	Highly established	Established	Established
Brand awareness	Moderate	High	Moderate	Moderate
Generic pressure	High	High	High	High
Dosing	Once daily	Once daily	Once daily	Once daily
Differentiation	Brand, formulation, dosing	Brand scale and extensions	Established allergy franchise	Established allergy franchise
Patent strength	Weak	Weak	Weak	Weak
Price risk	High	High	High	High

Nasonex’s principal disadvantage is its later OTC positioning relative to Flonase. Its principal opportunity is to use the Nasonex name and mometasone familiarity to win consumers who prefer the brand or who respond favorably to the product’s formulation.

Key Takeaways

Nasonex 24HR Allergy is an OTC mometasone furoate nasal spray marketed in a mature, genericized category.
The product has no meaningful current molecule-level patent barrier in the U.S.
Generic mometasone and competing OTC corticosteroids create immediate substitution and pricing risk.
Organon does not publicly disclose standalone Nasonex revenue or profit.
The OTC launch expanded consumer access but also increased reliance on retail execution, advertising, and seasonal demand.
Nasonex is unlikely to be a major consolidated revenue driver for Organon.
The product’s remaining commercial assets are its trademark, brand recognition, once-daily dosing, distribution, and consumer positioning.
No biosimilar risk applies because mometasone furoate is a small-molecule drug.
Long-term performance will depend more on share retention and price discipline than on patent enforcement.

FAQs About Nasonex 24HR Allergy

Is Nasonex 24HR Allergy the same as prescription Nasonex?

It contains the same active ingredient, mometasone furoate, but the OTC product has consumer-directed labeling and packaging. Prescription and OTC products can differ in regulatory approval details, labeling, and distribution.

Can generic mometasone replace Nasonex 24HR Allergy?

Generic mometasone nasal spray is a direct therapeutic substitute in prescription channels. Whether a consumer can substitute it without a prescription depends on the product’s regulatory status and applicable dispensing rules.

Does Nasonex have pediatric commercial potential?

Yes. Its labeling includes children aged two years and older, giving it access to a large pediatric allergy segment. Pediatric use also increases the importance of clear labeling, dosing compliance, and caregiver trust.

Is Nasonex more defensible than a store-brand nasal spray?

Nasonex has stronger trademark recognition and potentially better consumer trust, but its core active ingredient is not meaningfully protected by patents. Store brands can compete on price and retailer placement.

Could Organon license Nasonex to another consumer-health company?

A licensing or distribution transaction is commercially possible, but no current public disclosure establishes a major new Nasonex licensing deal. The product’s value would be assessed through brand equity, retail access, geographic rights, manufacturing economics, and marketing obligations.

References

U.S. Food and Drug Administration. (n.d.). DailyMed: Nasonex 24HR Allergy, mometasone furoate nasal spray. National Library of Medicine.
Organon & Co. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
Organon & Co. (2023). Form 10-K annual report. U.S. Securities and Exchange Commission.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	61
Patent Applications:	6,001
DailyMed Link:	NASONEX 24HR ALLERGY at DailyMed

Sponsor	Phase
National University of Malaysia	NA
Yingu Pharmaceutical Co., Ltd	Phase 4
Centre hospitalier de l'Université de Montréal (CHUM)	Phase 4

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Perrigo Pharma Intl	NASONEX 24HR ALLERGY	mometasone furoate	SPRAY, METERED;NASAL	215712-001	Mar 17, 2022		OTC	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for NASONEX 24HR ALLERGY

Recent Clinical Trials for NASONEX 24HR ALLERGY

Pharmacology for NASONEX 24HR ALLERGY